for of leading closing and April. started Standard million most my and speaking science be of Standard to Capital quarter Executive proud a going in infusion $XXX I'm forward. one-month evaluation as in the the company's role end this life everyone. and ago strategic just of Casdin BioTools of on completion you Hello, first Vikram. and the I Chief XXXX marked focus which therefore Officer President you, vision priorities Thank of process, The with our Viking today BioTools. comments culminated I'll capital from strategic investors Global
sales by the for our adversely our milestone related Vikram force. disappointing the this affected performance a major mentioned, of quarter closing in was While financial first transaction U.S. marked as and disruptions
growth, changed immediate and taking leadership, to essential BioTools to we our continued Mindful Davis life upon. industry. reflect will We the Chief disruptions, science its new chapter steps name as Officer. XXXX with Commercial the operational in provider a our to to on embark Standard We're new the foundation, as address of serve appointment we past our we will beginning, APAC. and and execution an including lessons, also To COVID-related become focused solutions now build recent new issues of ambition mark Jeremy the our experienced to particularly of which
achieve ambitious vision become and research tools science that to We an five offering customers their to our is company goal life become best-in-class by a three We'll company, quartile tools in established workflows. for our years. top in the this standards have
vision strategy Our to three pillars. has this realize
will focusing or we to prioritize growth growing we have efforts could First, market a our compete we by where believe in advantage. competitive segments have revenue
translational Specifically, more research. in servicing clinical customers we'll and focus on
for operating create significantly our best-in-class we value by all increase we discipline and so stakeholders. productivity expenses can more to improve implementing manage Second, will processes
Third, these to Allow leverage expand to infrastructure. each our we of allocation me offering us allow product acquire our with strategic on to that customers priorities. complementary elaborate intend assets strategic to our to capital
revenue Number priority believe cytometry is X Our growth, driver. growth will mass be our we and
mass customers. instrument, of in high-parameter the our barriers flow by the for adoption for key CyTOF our XT new addresses to technology Our expressed cytometry as cytometry some past,
translational to integrates throughput, sample valuable increases sectors. the reduces total introduction and biotechnology of improves researchers and automation, XT across results clinical and features CyTOF ownership, to Specifically, new pharmaceutical time cost particularly
reducing imaging Hyperion+ solve of results our competitive of position detecting lower high-plex at more full Our new imaging system is remarkable imaging researchers the are in faster critical believe growing designed Two market, system to system. to imaging than realizing challenges to low will transformative time prior questions We these with answer treatment. and deeper detection we'll of a a invest make this imaging our The offers to biological technology potential that continue limit are to Hyperion+ Hyperion+ our competitive. and levels. instruments challenges the time response understanding improve and disease the that and to key biomarkers important expressed in
our Jeremy as of decades expression, leverages operational is than experience Officer, genomics preparation Olink. improvements improving our be pull-through qPCR needs, HD improving business, of over sample-to-answer the assays our our platform business and world-class mass legacy Commercial is NGS more two it high-parameter an nano-scale associated a in Davis. decade with both manufacturing Leading brings known in proteomics and library across commercial workflow relationship make versatile, cytometry Biomark of address adding business consumable instruments Chief expansion, NGS X our imaging, driving integrates focus also service single X better per offerings, globe. and Juno to for we our biomarker in simplify automation Microfluidics flow the new centers Importantly, businesses efforts a capabilities intent in our customers' consumable invest gene through leadership, menu thereby will which and Biomark and instrument. and areas for the their to protein Biomark transformative through cytometry our will expansive on We're application currently such and genotyping, scalable, new a short-term. while into platform. and profitable to instrument, set launching our Jeremy as
scale. sufficient applications in focus forward, can we Going where on well-defined targeted will markets we achieve
with are We the growth which pleased driver of microfluidics. partnership, is performance a for the Olink
Leading will Healthcare President, We Milliken opportunities And he our be decade will microfluidics at Vice Kim, efforts leverage Chief Alex most Corporation. microfluidics Alex our was recently Previously, our technology. a Company. Officer. continue Business Alex Division Senior and Pall was Danaher. additional Operating prior in President spent in the to Corporate Development OEM Strategy to of that, seek for to &
our to As reach we broaden our offering, our service research. Currently, our customer in concentrated customer customer expand is goal and the is base. basic
and direct will marketing biotech our We the into sales provider expand CRO/CMO life broader diagnostic and science service the deeper emerging including companies large to ecosystem, relationships pharma, and network.
the and quarter, the already first XT XXX are CyTOF encouraging seeing underway CyTOF end were technology. adoption of segment. pharma, biotech in trials We the of clinical our CRO At using
how are do, also going be stakeholders, To foundational. we to are we a create going important journey value will highlight we will on it continuous Kaizen. because to what of improvement, discussed for or I to embark all As things do it's
the that focus by systematic Business aspect approach organizations the we and SBS, of the that work and processes leverage We approach highest-performing will on process close begin in standard journey problem-solving BioTools Standard System, business with this gap. One methodologies lean key used based a on to world. is operations to
We improve SBS as operating use structure. optimize we our our will discipline cost to
product product capital workflow leader particular expand strategic to to along SBS assets complementary roll This drive SBS, biological management a Accordingly, acquire that and to researchers, out customer Senior continuous transformation training in their to is broader and allocation leverage with BioTools Abou-Sayed. clinical transformation. our and upcoming us Mona offering Mona in translational is human product to requires experience meet intend to Vice this Standard operations, our President will want priority be in weeks. we provider pharma Leading we At infrastructure. in customers [ph], resources seasoned will organizational We that our have be research. needs. the the allows third offerings we cultural to a existing of a leading with improvement
We we decades. of cultivated over have developed potential a funnel identified robust which through today, relationships have acquisitions
with incoming Our on synergies de-risked, has potential and acquisitions immediate have focus that the technologically revenue in The successful existing team acquisitions. have be significant will management company's completing are experience infrastructure.
in about. we seeing approach. current market M&A can that We assets, will we intend market. which our strategically in given And and opportunities. such, we to As be be active tell in Particularly financially increase disciplined the actively we M&A you we're are engaged an the various excited dynamics, are in evaluating
refine health. to the in strategy journey. During to now team I'll events. process, the accelerate And forward will After I'm financial transformation Peter. embark look it. various completing course, this this as leading also investor confident to days, will at call appropriate over human indeed our at on tactical next breakthroughs to I additional time, our XX set look the we tool providing you of I forward outstanding the and our meeting to details execute that we turn to we forward look and finalize community. the plan
